Illumina, Inc. $ILMN Position Reduced by Keybank National Association OH

Keybank National Association OH trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 10.1% in the first quarter, HoldingsChannel.com reports. The firm owned 375,676 shares of the life sciences company’s stock after selling 42,312 shares during the quarter. Keybank National Association OH’s holdings in Illumina were worth $46,306,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Elyxium Wealth LLC bought a new stake in shares of Illumina in the 4th quarter worth $25,000. Creative Capital Management Investments LLC boosted its stake in Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after buying an additional 120 shares in the last quarter. Board of the Pension Protection Fund acquired a new position in Illumina during the fourth quarter worth about $26,000. TD Waterhouse Canada Inc. acquired a new position in Illumina during the fourth quarter worth about $26,000. Finally, Laurel Wealth Advisors LLC bought a new stake in Illumina in the fourth quarter worth about $26,000. 89.42% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Illumina news, CAO Scott D. Ericksen sold 500 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the completion of the sale, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at approximately $2,311,360. This represents a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the transaction, the director owned 2,830,452 shares of the company’s stock, valued at approximately $463,146,860.76. The trade was a 7.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,003,769 shares of company stock worth $155,710,908 in the last quarter. 2.90% of the stock is currently owned by corporate insiders.

Illumina Stock Up 2.6%

Shares of Illumina stock opened at $188.68 on Friday. The stock’s fifty day moving average is $153.57 and its 200-day moving average is $139.08. The firm has a market capitalization of $28.55 billion, a PE ratio of 34.31, a price-to-earnings-growth ratio of 3.44 and a beta of 1.47. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $189.46.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the company posted $0.97 EPS. Illumina’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities analysts anticipate that Illumina, Inc. will post 5.21 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ILMN shares. JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and upped their price target for the company from $125.00 to $185.00 in a report on Wednesday, June 10th. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Guggenheim boosted their target price on shares of Illumina from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Finally, Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a report on Thursday, May 14th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Illumina presently has a consensus rating of “Hold” and an average price target of $148.94.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.